171 related articles for article (PubMed ID: 20127951)
1. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.
Milenic DE; Brady ED; Garmestani K; Albert PS; Abdulla A; Brechbiel MW
Cancer; 2010 Feb; 116(4 Suppl):1059-66. PubMed ID: 20127951
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
Milenic DE; Garmestani K; Brady ED; Albert PS; Abdulla A; Flynn J; Brechbiel MW
Clin Cancer Res; 2007 Mar; 13(6):1926-35. PubMed ID: 17363549
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation.
Milenic DE; Baidoo KE; Shih JH; Wong KJ; Brechbiel MW
Cancer Biother Radiopharm; 2013; 28(6):441-9. PubMed ID: 23758610
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
5. Exploration of a F(ab')
Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.
Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
MAbs; 2015; 7(1):255-64. PubMed ID: 25587678
[TBL] [Abstract][Full Text] [Related]
7. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
Zou P; Povoski SP; Hall NC; Carlton MM; Hinkle GH; Xu RX; Mojzisik CM; Johnson MA; Knopp MV; Martin EW; Sun D
World J Surg Oncol; 2010 Aug; 8():65. PubMed ID: 20691066
[TBL] [Abstract][Full Text] [Related]
8. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.
Milenic DE; Garmestani K; Brady ED; Albert PS; Ma D; Abdulla A; Brechbiel MW
Cancer Biother Radiopharm; 2005 Oct; 20(5):557-68. PubMed ID: 16248771
[TBL] [Abstract][Full Text] [Related]
9. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.
Zou P; Xu S; Povoski SP; Wang A; Johnson MA; Martin EW; Subramaniam V; Xu R; Sun D
Mol Pharm; 2009; 6(2):428-40. PubMed ID: 19718796
[TBL] [Abstract][Full Text] [Related]
10. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
Domingo RJ; Reilly RM
Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.
Milenic D; Garmestani K; Dadachova E; Chappell L; Albert P; Hill D; Schlom J; Brechbiel M
Cancer Biother Radiopharm; 2004 Apr; 19(2):135-47. PubMed ID: 15186593
[TBL] [Abstract][Full Text] [Related]
12. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
Greiner JW; Ullmann CD; Nieroda C; Qi CF; Eggensperger D; Shimada S; Steinberg SM; Schlom J
Cancer Res; 1993 Feb; 53(3):600-8. PubMed ID: 8425194
[TBL] [Abstract][Full Text] [Related]
13. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.
Milenic DE; Baidoo KE; Kim YS; Barkley R; Brechbiel MW
Dalton Trans; 2017 Oct; 46(42):14591-14601. PubMed ID: 28675216
[TBL] [Abstract][Full Text] [Related]
15. Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma.
Greiner JW; Guadagni F; Roselli M; Ullmann CD; Nieroda C; Schlom J
Dis Colon Rectum; 1994 Feb; 37(2 Suppl):S100-5. PubMed ID: 8313780
[TBL] [Abstract][Full Text] [Related]
16. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
18. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Mol Cancer Ther; 2012 Mar; 11(3):639-48. PubMed ID: 22238365
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
20. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
